Evicenter
P&T meetings

Tinlarebant (LBS-008)

Stargardt disease type 1

Manufacturer
Belite Bio
Regulatory submission
NDA submitted June 2026
Last updated
66 sources

Product information and disease descriptionProduct description

Product information

17 evidence topics · 17 sources

Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification

No evidence found.

Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Co-prescribed/Concomitant therapies

No evidence found.

Effect of Tinlarebant on quality measures

No evidence found.

Product comparison